Protara Therapeutics, Inc.(TARA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Protara Therapeutics, Inc. (TARA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TARA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.9m in revenue and is scored on the micro-cap board instead. Top institutional holders of TARA by reported 13-F value include Jupiter Topco, BlackRock, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. TARA trades on the Nasdaq exchange and files with the SEC under CIK 1359931. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TARA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protara Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-21.7M

TARA key financials by period

Protara Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201410-K$2.9M$-3.3M—

Institutions holding TARA

Institutional investors reporting a position in Protara Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
Jupiter Topco4,696,709$17.9M2026-06-30
BlackRock3,663,499$14.0M2026-06-30
MILLENNIUM MANAGEMENT3,101,166$11.8M2026-06-30
Velan Capital Investment Management2,844,652$10.9M2026-06-30
VANGUARD CAPITAL MANAGEMENT2,300,133$8.8M2026-06-30
Blackstone2,265,514$8.7M2026-06-30
ORBIMED ADVISORS2,220,000$8.5M2026-06-30
Sio Capital Management1,921,872$7.3M2026-06-30
ACORN CAPITAL ADVISORS1,752,115$6.7M2026-06-30
Integral Health Asset Management1,500,000$5.7M2026-06-30
SEC EDGAR: CIK 1359931 →
TARA

Protara Therapeutics, Inc.

TARA
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-21.67M

EPS (Diluted)

Q2 2026
EDGAR

$-0.36

ROIC

Q2 2026
EDGAR

-57.8%

Top Institutional Holders

as of Q2 2026
$176.28M total
Jupiter Topco LLC
$17.92MNew
BlackRock, Inc.
$13.99M+7.9%
MILLENNIUM MANAGEMENT LLC
$11.85M+9.5%
Velan Capital Investment Management LP
$10.87M+0.4%
VANGUARD CAPITAL MANAGEMENT LLC
$8.79M+8.5%
Blackstone Inc.
$8.65M0.0%
ORBIMED ADVISORS LLC
$8.48MNew
Sio Capital Management, LLC
$7.34M-2.4%
ACORN CAPITAL ADVISORS, LLC
$6.69M0.0%
Integral Health Asset Management, LLC
$5.73M-14.3%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…